SCHEMBL12430388

SCHEMBL12430388

CC(C)(C)c1c[nH]c2nc(N)nc(O)c12

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHUK O15111 11/20 0.38
IKBKB O14920 3/20 0.37
HSP90AA1 P07900 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11986721 0.77 CHUK (0.41) CHUKIKBKB
SCHEMBL30975034 0.76 IRAK4 (0.47) IRAK4
SCHEMBL24811750 0.74 CHEK1 (0.41) CHUKIKBKB
SCHEMBL14197880 0.73 CHUK (0.38) CHUKIKBKBIRAK4
SCHEMBL24630170 0.73 CHUK (0.40) CHUKIKBKB
SCHEMBL3793648 0.69 DYRK1A (0.42)
SCHEMBL25902962 0.67 CHUK (0.33) CHUKIKBKB
SCHEMBL23815869 0.67 IRAK4 (0.48) IRAK4
SCHEMBL10306798 0.65 DHFR (0.48) CHUKIKBKB
SCHEMBL26773875 0.64 IRAK4 (0.37) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed
EP-2117552-B1 USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES STOICESCU DAN (CH) 2011-08-03 EP disclosed
US-7875716-B2 Such as n-[4-[[2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]pseudoglutamic ester; synthesis; efficacy; reduced renal toxicity and other adverse side effects; cancer STOICESCU DAN 2011-01-25 US disclosed
US-20080214550-A1 Novel inhibitors of folic acid-dependent enzymes STOICESCU DAN 2008-09-04 US disclosed
US-20080207652-A1 Novel inhibitors of folic acid-dependent enzymes STOICESCU DAN 2008-08-28 US disclosed
WO-2008098957-A1 USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES STOICESCU DAN (CH) 2008-08-21 WO disclosed
EP-1958632-A1 Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases Stoicescu, Dan (CY) 2008-08-20 EP disclosed
EP-1809292-B1 CONDENSED PYRIMIDINE DERIVATIVES AS INHIBITORS OF FOIC ACID-DEPENDENT ENZYMES STOICESCU DAN (CH) 2008-05-21 EP disclosed
WO-2007020277-A2 CONDENSED PYRIMIDINE DERIVATIVES AS INHIBITORS OF FOIC ACID-DEPENDENT ENZYMES STOICESCU DAN (CY) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A CHUK 2864/4885IKBKB 1573/4885HSP90AA1 4496/4885
US-20080207652-A1 Novel inhibitors of folic acid-dependent enzymes FOLR2, FOLR1, DHFR CHUK 972/4885IKBKB 2631/4885HSP90AA1 4819/4885
US-20080214550-A1 Novel inhibitors of folic acid-dependent enzymes FOLR2, FOLR1, DHFR CHUK 984/4885IKBKB 2553/4885HSP90AA1 4815/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B CHUK 2853/4885IKBKB 1642/4885HSP90AA1 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.